feasibility study on CPT-11/TS-1 sequential therapy for TS-1-resistant unresectable gastric cancer

feasibility study on CPT-11/TS-1 sequential therapy for TS-1-resistant unresectable gastric cancer - feasibility study on CPT-11/TS-1 sequential therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000270

Enrollment

Registered

2011-09-01

Start date

2004-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

TS-1 is administered after CPT-11 and the effect is evaluated.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: a pathologically-diagnosed gastric cancer unresectable advanced/reccurrent case bearing measurable or evaluable lesion relapsed case after TS-1-based chemotherapy without CPT-11 as the first-line therapy WBC 3500-12000,neutrocyte>2000, platelet>100000, Hb >9.0,T-bil <=1.5 ECOG PS 0-2 oral intake at least 3-month survival estimated written informed consent by patient

Exclusion criteria

Exclusion criteria: infection diarrhea colon paralysis or obstruction interstitial pneumonia or pulmonary fibrosis massive ascites or pleural effusion jaundice hypersensitivity against CPT-11 or S-1 co-administration with 5-flucytosine pregnant or its possibility multiple cancers other severe complications a patient judged as an inadequate case by his doctor

Design outcomes

Primary

Measure	Time frame
anti-tumor effect	—

Secondary

Measure	Time frame
overall survival and progression-free survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026